Group 1 - Xindong Company (02400) reported a positive earnings forecast, expecting revenue of at least RMB 3.05 billion for the first half of 2025, a year-on-year increase of approximately 37%, and a net profit of at least RMB 790 million, a year-on-year increase of about 215% [1] - Yimai Sunshine (02522) also announced a positive earnings forecast, expecting revenue between RMB 450 million to 480 million for the first half of the year, a year-on-year increase of approximately 8.77% to 16.03%, and a net profit of RMB 14.5 million to 16.5 million, a year-on-year increase of about 1350% to 1550% [1] - Tianli International Holdings (01773) plans to repurchase shares up to a total of HKD 200 million based on market conditions, believing that the share buyback plan is in the best interest of the company and its shareholders [2] Group 2 - Liaogang Co., Ltd. (02880) reported a total operating revenue of RMB 5.693 billion for the first half of 2025, a year-on-year increase of 5.93%, and a net profit attributable to shareholders of RMB 956 million, a year-on-year increase of 110.78% [2] - Yuan Zheng Technology (02488) reported a revenue of RMB 982 million for the first half of 2025, a year-on-year increase of 9.75%, and a net profit of RMB 195 million, a year-on-year increase of 27.74% [2] - Geekplus Technology (02590) expects revenue between RMB 995 million to 1.03 billion for the first half of the year, a year-on-year increase of 27% to 32%, while the net loss is expected to narrow significantly [3] Group 3 - Lee & Man Paper Manufacturing (02314) and other leading companies in the paper industry have initiated a price increase for various products starting August 1, indicating a significant acceleration in price adjustment frequency within the industry [3] - Xinda Biopharmaceutical (01801) announced that its innovative oral small molecule GLP-1R agonist IBI3032 has received IND approval from the FDA [4] - Heyu-B (02256) reported a revenue of RMB 612 million for the first half of the year, a year-on-year increase of 23.1%, and a net profit of RMB 328 million, a year-on-year increase of 58.84% [4] Group 4 - Bilibili (BILI.US) is expected to achieve a revenue growth of 20% year-on-year to RMB 7.3 billion in the second quarter, driven by stable performance in mobile games [5][6] - Li Auto (LI.US) launched the Li Xiang i8, with deliveries starting on August 20, and received positive outlooks from multiple institutions [6] - Xpeng Motors (XPEV.US) achieved a new monthly delivery record in July, delivering 36,717 smart electric vehicles, a year-on-year increase of 229% [7]

消息面上，一脉阳光发布盈喜，预计上半年收入4.5亿至4.8亿元人民币，同比增长约8.77%至16.03%； 纯利1450万元至1650万元人民币，同比增长约1350%至1550%。董事会认为，收入增加主要是由于公司 的客户数目及所交付的服务数目增加，纯利增加乃主要由于上述于有关期间的收入较2024年同期增加及 行政开支的减少。 值得注意的是，一脉阳光近期发布公告，公司董事会已审议及批准公司若干股东所持公司1.04亿股未上 市股份(占公司于本公告日期已发行股本总额的约28.46%)拟实施全流通。于本公告日期，H股全流通仍 有待取得所有相关批准(包括中国证监会的备案通知)、将该等未上市股份转换为公司H股及香港联合交 易所有限公司批准该等H股于联交所主板上市及买卖。 智通财经获悉，一脉阳光(02522)高开逾7%，截至发稿，涨7.49%，报14.49港元，成交额1266.43万港 元。 本文源自智通财经网 ...

Core Viewpoint - The company, Yimai Sunshine (02522), has announced a positive earnings forecast, leading to a significant increase in its stock price, reflecting strong revenue and profit growth expectations for the first half of the year [1] Financial Performance - The company expects revenue for the first half of the year to be between 450 million to 480 million RMB, representing a year-on-year growth of approximately 8.77% to 16.03% [1] - The projected net profit is between 14.5 million to 16.5 million RMB, indicating a substantial year-on-year increase of approximately 1350% to 1550% [1] - The increase in revenue is attributed to a rise in the number of customers and services delivered, while the profit growth is mainly due to increased revenue compared to the same period in 2024 and a reduction in administrative expenses [1] Shareholder Actions - The company's board has approved the full circulation of 104 million unlisted shares held by certain shareholders, which accounts for approximately 28.46% of the total issued share capital as of the announcement date [1] - The full circulation of H-shares is pending approval from relevant authorities, including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1]

Core Viewpoint - The company, Yimai Sunshine (02522), has announced a positive earnings forecast, leading to a significant increase in its stock price, reflecting strong revenue and profit growth expectations for the first half of the year [1] Financial Performance - The company expects revenue for the first half of the year to be between 450 million to 480 million RMB, representing a year-on-year growth of approximately 8.77% to 16.03% [1] - Projected net profit is estimated to be between 14.5 million to 16.5 million RMB, indicating a substantial year-on-year increase of approximately 1350% to 1550% [1] - The increase in revenue is attributed to a rise in the number of customers and services delivered, while the profit increase is mainly due to higher revenue compared to the same period in 2024 and a reduction in administrative expenses [1] Shareholder Actions - The company's board has approved the full circulation of 104 million unlisted shares held by certain shareholders, which accounts for approximately 28.46% of the total issued share capital as of the announcement date [1] - The full circulation of H-shares is pending approval from relevant authorities, including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1]

Core Viewpoint - The company anticipates a significant increase in revenue and net profit for the six months ending June 30, 2025, compared to the same period in 2024, driven by an increase in customer numbers and services delivered [1] Revenue Summary - The company expects revenue to be between approximately RMB 450 million and RMB 480 million for the six months ending June 30, 2025, compared to approximately RMB 413.7 million for the same period in 2024, representing a year-on-year growth of approximately 8.77% to 16.03% [1] Net Profit Summary - The anticipated net profit for the six months ending June 30, 2025, is expected to be between approximately RMB 14.5 million and RMB 16.5 million, a substantial increase from approximately RMB 1 million for the same period in 2024, indicating a year-on-year growth of approximately 1350% to 1550% [1] Factors Contributing to Growth - The board attributes the increase in revenue compared to 2024 to a rise in the number of customers and services delivered, while the significant increase in net profit is primarily due to the rise in revenue and a reduction in administrative expenses [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 於本公告日期，本公司仍在審定本集團於有關期間的中期業績。本公告所載資料 僅基於本公司管理層參照本集團於有關期間的未經審核管理賬目及董事會現時可 獲得的資料而作出的初步評估，該等資料並未經本公司核數師或審計委員會審核 或審閱。本集團有關期間的實際業績可能與本公告所披露者存在差異。根據上市 規則，本集團於有關期間的中期業績公告預期於2025年8月31日或之前公佈。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 正面盈利預告 本公告乃江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司，「本集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及證 券及期貨條例（香港法例第571章）第XIVA部項下 ...

（股份代號：2522） 內幕消息 本公司擬實施H股全流通 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公告乃江西一脈陽光集團股份有限公司（「本公司」）根據香港聯合交易所有限公 司證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條 例第XIVA部項下的內幕消息條文（定義見上市規則）而刊發。 H股全流通及轉換及上市須遵守中國證監會、聯交所及其他境內外監管機構 要求的相關程序。本公司股東及有意投資者於買賣本公司證券時務請審慎行 事。 承董事會命 茲提述中國證券監督管理委員會（「中國證監會」）於2019年11月14日發佈並於 2023年8月10日進一步修訂的《H股公司境內未上市股份申請「全流通」業務指引》 （「該指引」）。 鑒於該指引，本公司董事（「董事」）會（「董事會」）已審議及批准 ...

Core Insights - The National Medical Products Administration (NMPA) has announced measures to optimize the lifecycle regulation of high-end medical devices, focusing on areas such as medical robots, high-end medical imaging equipment, AI medical devices, and new biological materials [1] - The global high-end medical device market is projected to exceed $1.8 trillion by 2030, with China's market expected to reach 2.8 trillion RMB [1] Industry Focus Areas - **Brain-Computer Interface (BCI)**: The BCI market in China is expected to reach 3.2 billion RMB in 2024, growing at 18.8%, and is projected to reach 5.58 billion RMB by 2027 with a growth rate of 20%. Challenges include technical bottlenecks and ethical controversies [2] - **High-End Medical Imaging Equipment**: The domestic market has seen rapid development, with increasing localization in mid-to-low-end products. However, high-end imaging equipment still faces challenges, particularly in the localization of key components [2] - **Surgical Robots**: The market for surgical robots is dominated by laparoscopic surgical robots, with the Da Vinci system currently leading. Domestic products are entering the market, which may disrupt the current landscape [3] - **High-Value Consumables**: These account for about 20% of the medical device market. While some segments have achieved domestic substitution, others, particularly in cardiac and neurological devices, still rely heavily on imports [3] - **In Vitro Diagnostics (IVD)**: The IVD industry has seen significant domestic advancement in low-end technologies, but high-end segments remain largely dominated by foreign brands [3] Market Trends - The medical device industry is characterized by a dual focus on technology-driven innovation and domestic substitution. Key components for high-end devices are being developed domestically, with some products nearing international standards [4] Related Companies - **MicroPort Scientific Corporation (微创机器人)**: Reported over 130 core product orders, with significant growth in laparoscopic surgical robots [5] - **Yimai Sunshine (一脉阳光)**: Engaged in building medical imaging centers and has launched an AI medical imaging model, marking a transition in the industry [6] - **Yongsheng Medical (永胜医疗)**: Focuses on rehabilitation robotics and has secured agreements for health care product procurement [6] - **Kangji Medical (康基医疗)**: Recently received regulatory approval for a four-arm laparoscopic surgical robot, expanding its clinical application range [7]

Core Viewpoint - The recent acquisition of 70% stake in Gao Mai Health by Yimai Yangguang (02522) is seen as a strategic move to enhance its position in the nuclear medicine sector, indicating a potential for value re-evaluation in the company and the industry as a whole [1][3][10]. Group 1: Company Developments - Yimai Yangguang has seen a significant increase in trading activity, with an average daily trading volume of approximately HKD 280 million over the past 12 trading days, indicating strong market interest [1]. - The company's management collectively purchased 208,000 H-shares, signaling confidence in the company's future and suggesting that the stock is undervalued [1]. - Following the acquisition announcement, the company's stock price surged over 10%, reflecting market recognition of the potential value creation from the deal [12]. Group 2: Strategic Positioning - The acquisition of Gao Mai Health completes a critical piece of Yimai Yangguang's nuclear medicine strategy, creating a full industry chain that integrates imaging services, nuclear medicine, and AI [3][4]. - The company aims to establish a "drug-service-data-AI" integrated business model, enhancing its market leadership and operational capabilities [4][5]. - The "One County, One Nuclear Medicine" policy is expected to accelerate the company's growth, as it leverages its unique resources and data assets to drive performance [1][4]. Group 3: Industry Trends - The third-party medical imaging industry is undergoing a significant transformation, with mergers and acquisitions expected to increase from HKD 2.8 billion in 2021 to HKD 9.2 billion by 2024, reflecting a compound annual growth rate of 48% [8]. - The industry is shifting from being a "supporting role" in healthcare to becoming a "core node" in the health industry, driven by policy, capital, and technological advancements [8][9]. - Yimai Yangguang's strategic positioning is seen as a benchmark for value re-evaluation in the third-party medical imaging sector, as it integrates technology, data, and business models [10][12].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 江西一脈陽光集團股份有限公司 （股份代號：2522） 自願公告 若干董事購買本公司H股 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出。 於2025年6月24日，董事會獲悉(i)本公司董事長、執行董事兼行政總裁陳朝陽先 生；(ii)本公司執行董事、副總裁、聯席公司秘書兼董事會秘書何英飛女士；及 (iii)本公司執行董事、副總裁兼本公司首席財務官馮勰先生（統稱「相關董事」）於 2025年6月23日及2025年6月24日以自有資金在公開市場購買總計208,000股本公 司H股（「H股」）（「增持」）。相關董事已告知董事會彼等對本集團 ...